STOCK TITAN

Delcath Systems (DCTH) Stock News, Aug-Oct 2023

DCTH NASDAQ

Delcath Systems, Inc. develops interventional oncology products for primary and metastatic liver cancers. Its core products include HEPZATO KIT, a melphalan and Hepatic Delivery System combination product approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma, and CHEMOSAT Hepatic Delivery System for Melphalan used in percutaneous hepatic perfusion.

Recurring news covers quarterly operating results, HEPZATO KIT and CHEMOSAT revenue, clinical publications from studies such as FOCUS and CHOPIN, presentations at oncology and interventional radiology meetings, guideline recognition, and studies of melphalan-based percutaneous hepatic perfusion in liver-dominant cancers. Company updates also address FDA-approved product status, European clinical practice references, and capital actions such as common-stock repurchases.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.07%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.14%
Tags
conferences
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.24%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
81.73%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.54%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
conferences earnings

FAQ

What is the current stock price of Delcath Systems (DCTH)?

Delcath Systems (DCTH) last closed at $19.37.

What is the market cap of Delcath Systems (DCTH)?

The market cap of Delcath Systems (DCTH) is approximately $673.8M.